Genovis GENO.ST · SEK

Its shares trade on Nasdaq Stockholm under the ticker GENO.ST. It has been listed since 11 November 2005. In the fiscal year to 31 December 2025, it reported revenue of SEK 128.9m and net income of SEK 23.5m. At that date it held total assets of SEK 377.9m and shareholders' equity of SEK 271.5m.

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Torben JorgensenIndependent Chairman of the BoardSEK 496,000
• Mr. Fredrik OlssonChief Executive Officer, since 2015SEK 3.5m
• Mr. Magnus LangbergChief Financial Officer
• Ms. Rikke RytterVice President - Sales and Marketing
• Mr. Stephan BjorkVice President - Production
• Ms. Helen NyhlenVice President - Quality Assurance
• Mr. Rolf LoodVice President - Research and Development
• Mr. Mikael LoennDirectorSEK 231,000
• Mr. Magnus GustafssonIndependent DirectorSEK 276,000
• Mr. Steve JordanIndependent DirectorSEK 210,000
• Ms. Charlotta LjungqvistIndependent DirectorSEK 276,000

Overall

22

Environment

8

Social

26

Governance

33

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.